PetMed Express D/B/A 1-800-PetMeds Announces Third Quarter Financial Results


Net Sales Increased 12% to $50.5 Million
New Order Sales Increased 29% to $10.1 Million
Online Sales Increased 19% to $38.7 Million

POMPANO BEACH, Fla., Jan. 23, 2012 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (Nasdaq:PETS) today announced its financial results for the quarter ended December 31, 2011. Net sales for the quarter ended December 31, 2011 were $50.5 million, compared to $45.1 million for the quarter ended December 31, 2010, an increase of 12%. Net sales for the nine months ended December 31, 2011 were $182.3 million, compared to $180.7 million for the nine months ended December 31, 2010, an increase of 1%. Net income was $3.9 million or $0.19 diluted per share for the quarter ended December 31, 2011, compared to net income of $4.5 million or $0.20 diluted per share for the quarter ended December 31, 2010, a 3% decrease to EPS. For the nine months ended December 31, 2011, net income was $12.7 million or $0.61 diluted per share, compared to net income of $16.7 million or $0.74 diluted per share for the nine months ended December 31, 2010, a decrease to earnings per share of 17%. New order sales increased by 29%, from $7.8 million to $10.1 million for the quarters ended December 31, 2010 and 2011, respectively. New order sales for the nine months ended December 31, 2011 were $39.8 million, compared to $37.9 million for the nine months ended December 31, 2010, an increase of 5%. 

Menderes Akdag, President and CEO, commented: "We are pleased to report that we acquired 150,000 new customers in the quarter ended December 31, 2011, compared to 111,000 new customers acquired for the same period in the prior year, a 35% increase. Our advertising cost to acquire a new customer decreased by 11% to $36 for the quarter ended December 31, 2011, compared to $40 for the same period in the prior year. We are also pleased to report that our online sales increased by 19% to $38.7 million for the quarter, compared to $32.4 million for the same quarter the prior year, with approximately 77% of our orders being generated from our website during the quarter, compared to 72% in the same quarter in the prior year. Our reorder sales increased by 8% to $40.5 million for the quarter compared to $37.3 million for the same quarter the prior year.  During the quarter, the Company leveraged its operating expenses as a percent of sales, by 92 basis points as compared to the same quarter in the prior year. Going forward, we will continue to advertise aggressively while expanding our product offerings, which include generic pet medications."

This morning at 8:30 A.M. Eastern Time, Mr. Akdag will host a conference call to review the quarter's financial results. To access the call, which is open to the public, please dial (888) 455-1758 (toll free) or (210) 234-0009. Callers will be required to supply PETMEDS as the passcode. For those unable to participate in the live event, the call will be available for replay from 10:00 A.M. Eastern Time on January 23, 2012 until February 6, 2012 at 10:59 P.M. Eastern Time. To access the replay, call (888) 562-3875 (toll free) or (203) 369-3173, and enter passcode 5500.

Founded in 1996, PetMed Express is America's Largest Pet Pharmacy, delivering prescription and non-prescription pet medications and other health products for dogs and cats at competitive prices direct to the consumer through its 1-800-PetMeds toll free number and on the Internet through its website at www.1800petmeds.com.

This press release may contain "forward-looking" statements, as defined in the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission, that involve a number of risks and uncertainties, including the Company's ability to meet the objectives included in its business plan. Important factors that could cause results to differ materially from those indicated by such "forward-looking" statements are set forth in Management's Discussion and Analysis of Financial Condition and Results of Operations in the PetMed Express Annual Report on Form 10-K for the year ended March 31, 2011. The Company's future results may also be impacted by other risk factors listed from time to time in its SEC filings, including, but not limited to, the Company's Form 10-Q and its Annual Report on Form 10-K. For investment relations contact PetMed Express, Inc., Bruce S. Rosenbloom, CFO, 954-979-5995.

 
PETMED EXPRESS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
 
  December 31, March 31,
  2011 2011
  (Unaudited)  
ASSETS    
     
Current assets:    
Cash and cash equivalents  $ 41,965  $ 49,660
Short term investments - available for sale  10,300  10,116
Accounts receivable, less allowance for doubtful accounts of $5 and $6, respectively  1,639  1,985
Inventories - finished goods  25,946  25,140
Prepaid expenses and other current assets  2,013  1,036
Deferred tax assets  1,216  1,003
Prepaid income taxes  102  664
Total current assets  83,181  89,604
     
Long term investments  1,480  12,390
Property and equipment, net  2,882  3,433
Intangible asset  860  860
     
Total assets  $ 88,403  $ 106,287
     
LIABILITIES AND SHAREHOLDERS' EQUITY    
     
Current liabilities:    
Accounts payable  $ 6,141  $ 6,452
Accrued expenses and other current liabilities  2,090  2,509
Total current liabilities  8,231  8,961
     
Deferred tax liabilities  359  321
     
Total liabilities  8,590  9,282
     
Commitments and contingencies    
     
Shareholders' equity:    
Preferred stock, $.001 par value, 5,000 shares authorized; 3 convertible shares issued and outstanding with a liquidation preference of $4 per share 9 9
Common stock, $.001 par value, 40,000 shares authorized; 20,338 and 22,331 shares issued and outstanding, respectively  20  22
Retained earnings  79,774  97,115
Accumulated other comprehensive gain (loss)  10  (141)
     
Total shareholders' equity  79,813  97,005
     
Total liabilities and shareholders' equity  $ 88,403  $ 106,287
 
 
 PETMED EXPRESS, INC. AND SUBSIDIARIES 
 CONDENSED CONSOLIDATED STATEMENTS OF INCOME 
 (In thousands, except for per share amounts) (Unaudited) 
         
   Three Months Ended   Nine Months Ended 
   December 31,   December 31, 
  2011 2010 2011 2010
         
Sales   $ 50,523  $ 45,118  $ 182,326  $ 180,732
Cost of sales   33,369  28,193  121,128  114,251
         
Gross profit   17,154  16,925  61,198  66,481
         
Operating expenses:         
General and administrative   5,244  5,096  16,952  17,017
Advertising   5,449  4,444  23,453  21,859
Depreciation   359  358  1,046  1,023
Total operating expenses   11,052  9,898  41,451  39,899
         
Income from operations   6,102  7,027  19,747  26,582
         
Other income (expense):         
Interest income, net   70  98  228  265
Other, net   (1)  (144)  62  (111)
Total other income (expense)   69  (46)  290  154
         
Income before provision for income taxes   6,171  6,981  20,037  26,736
         
Provision for income taxes   2,273  2,459  7,372  10,011
         
Net income   $ 3,898  $ 4,522  $ 12,665  $ 16,725
         
Net income per common share:         
Basic   $ 0.19  $ 0.20  $ 0.61  $ 0.74
Diluted   $ 0.19  $ 0.20  $ 0.61  $ 0.74
         
Weighted average number of common shares outstanding:       
Basic   20,082  22,506  20,788  22,614
Diluted   20,180  22,655  20,886  22,755
         
Cash dividends declared per common share   $ 0.125  $ 0.125  $ 0.375  $ 0.350
 
 
PETMED EXPRESS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands) (Unaudited)
 
   Nine Months Ended 
   December 31, 
  2011 2010
Cash flows from operating activities:     
Net income   $ 12,665  $ 16,725
Adjustments to reconcile net income to net cash provided by operating activities:     
Depreciation   1,046  1,023
Share based compensation   1,686  1,606
Deferred income taxes   (175)  202
Bad debt expense   40  30
(Increase) decrease in operating assets and increase (decrease) in liabilities:     
Accounts receivable   306  1,265
Inventories - finished goods   (806)  14,179
Prepaid income taxes   562  (541)
Prepaid expenses and other current assets   (977)  (1,238)
Accounts payable   (182)  (1,532)
Accrued expenses and other current liabilities   (443)  (246)
Net cash provided by operating activities   13,722  31,473
     
Cash flows from investing activities:     
Net change in investments   10,877  (10,104)
Purchases of property and equipment   (624)  (491)
Purchases of intangible asset   --   (10)
Net cash provided by (used in) investing activities   10,253  (10,605)
     
Cash flows from financing activities:     
Dividends paid   (7,914)  (7,933)
Purchases of treasury stock   (23,685)  (5,225)
Tax adjustment related to restricted stock   (71)  25
Proceeds from the exercise of stock options   --   252
Tax benefit related to stock options exercised   --   124
Net cash used in financing activities   (31,670)  (12,757)
     
Net (decrease) increase in cash and cash equivalents   (7,695)  8,111
Cash and cash equivalents, at beginning of period   49,660  53,143
     
Cash and cash equivalents, at end of period   $ 41,965  $ 61,254
     
Supplemental disclosure of cash flow information:     
     
Cash paid for income taxes   $ 7,056  $ 10,254
     
Property and equipment purchases in accounts payable   $ --   $ 259
     
Dividends payable in accrued expenses   $ 167  $ 126


            

Tags


Kontaktdaten

GlobeNewswire